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Rapid tests (RTs) can be used as an alternative method for the conventional diagnosis of hepatitis B virus (HBV). 
This study aims to evaluate antibodies to HBsAg (anti-HBs) and antibodies to HBeAg (anti-HBe) RTs under dif-
ferent Brazilian settings. The following three groups were included: GI: viral hepatitis outpatient services; GII: low 
resource areas; and GIII: crack users and beauticians. Imuno-rápido anti-HBsAg™ and Imuno-rápido anti-HBeAg™ 
RTs were evaluated and showed specificities greater than 95% in all groups. The sensitivity values to anti-HBs were 
50.38%, 51.05% and 46.73% and the sensitivity values to anti-HBe were 76.99%, 10.34% and 11.76% in the GI, GII 
and GIII groups, respectively. The assays had a low sensitivity and high specificity, which indicated their use for 
screening in regions endemic for HBV.
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Approximately 240 million individuals are chronically 
infected with hepatitis B virus (HBV) worldwide. Annual-
ly, 780,000 people die due to late-stage complications, such 
as cirrhosis and hepatocellular carcinoma (WHO 2015). In 
Brazil, between 2000 and 2012, 120,343 confirmed HBV 
cases were reported (BMH 2015). HBsAg prevalence is 
0.63% in the north region, 0.31% in the midwest region 
and 0.31% in the southeast region (BMH 2015). Addition-
ally, HBsAg prevalence among different groups (children, 
beauticians and crack users) is low (0% to 6.2%) in Rio de 
Janeiro (Santos-Cruz et al. 2013, Villar et al. 2014a, b).
During HBV infection, markers can be detected in 
sera samples using immunoassays. For example, patient 
sera that contain anti-HBs indicates immunity from past 
infections or vaccinations, and a patient with anti-HBe 
antibodies in their sera is considered as spontaneous 
resolution of infection or therapy-induced improvement 
(Gerlich 2013, Villar et al. 2015).
A diagnosis of HBV is done using enzyme immuno-
assays (EIAs) and electrochemiluminescence (ECLIA) 
(Gerlich 2013, Villar et al. 2015). However, the use of these 
assays in real-life conditions in low and middle-income 
countries has been challenging due to the relatively long 
period of execution, the necessity of well-trained personnel, 
good infrastructure and logistics (Soeung et al. 2009).
RTs are simple, easy, cheap and fast. Currently, sev-
eral commercial RTs for HBsAg detection are available 
in Brazil, and BMoH has established policies and guide-
lines for HBsAg RT use (BMH 2016). The application of 
RTs as a substitute for conventional diagnoses of HBV 
infection may provide distinct advantages. Results are 
available in a few minutes, and RT use is feasible in poor 
infrastructure laboratories. HBsAg testing has shown 
high sensitivity, but some assays did not detect this mark-
er, especially in low endemicity regions, such as Latin 
America. In these settings, it is recommended that addi-
tional HBV testing should be utilised for detecting other 
serological markers. Currently, few laboratories use RTs 
for other HBV markers, such as anti-HBs and anti-HBe. 
These assays could increase the identification of suscep-
tible individuals for HBV vaccination and help in moni-
toring treatment response. Thus, in the present study, 
we evaluated the applicability of RTs for the detection 
of anti-HBs and anti-HBe markers in different groups to 
increase the availability of diagnosis in remote areas.
All individuals or parents/legal guardians signed the 
informed consent approved by the Ethics Committee 
of FIOCRUZ before recruitment. Serum samples were 
obtained from February 2009 to September 2013 from 
subjects who represented the following:
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Group I (GI) - Consisted of 423 and 166 individuals 
who donated serum samples for the anti-HBs and anti-
HBe RT evaluations, respectively. Individuals were re-
ferred from Viral Hepatitis Ambulatory (Oswaldo Cruz 
Foundation, FIOCRUZ). These individuals had suspect-
ed cases of viral hepatitis, and most of them lived in low 
socioeconomic areas in Rio de Janeiro state. Individuals 
were included if they were 18 years old or older, present-
ed with either symptomatic or asymptomatic hepatitis, 
and had one or more risk factors for HBV infection.
Group II (GII) - Contained 1,526 and 788 individu-
als who donated serum samples for the anti-HBs and 
anti-HBe RT evaluations, respectively. These individu-
als lived in the following regions in Brazil: (1) Midwest 
Region - individuals from Pantanal of Mato Grosso do 
Sul state, a rural area 385 km from the capital of state, 
Campo Grande City; (2) North Region - subjects from 
rural communities in the city of Tocantinópolis in To-
cantins state, 30 km from the urban area of the city; and 
(3) Southeast Region - employees from a private hospital 
located in Petrópolis and subjects living in an under-
privileged community in Macaé (both cities in Rio de 
Janeiro). Individuals were included if they were not pre-
viously diagnosed as HBV infected.
Group III (GIII) - Consisted of 381 and 241 individu-
als who donated serum samples for the anti-HBs and anti-
HBe RT evaluations, respectively. This group of individ-
uals was considered to be highly vulnerable individuals 
(crack users in the southeast region of Brazil and beauty 
professionals in Rio de Janeiro state) likely to acquire or 
already have an HBV infection. Individuals included in 
this group were active crack users and beauticians, in-
cluding manicurists, pedicurists, and hairdressers.
Sera samples were assayed for HBsAg, anti-HBc to-
tal, anti-HBc IgM and anti-HBs using commercial EIAs 
(Diasorin, Italy) and anti-HBe and HBeAg using com-
mercial ECLIA (Elecsys anti-HBe and HBe, Roche Di-
agnostics, Mannheim, Germany) according to the manu-
facturer’s instructions. The OD/CO of positive/negative 
samples was defined according to the manufacturer for 
each test. All reactive samples were retested using the 
same assay in duplicate.
Both Imuno-rápido anti-HBsAg™ and Imuno-rápido 
anti-HBeAg™ RTs were evaluated (Wama, Minas Gerais, 
Brazil). According to the manufacturer’s instructions, the 
assays had 100% sensitivity and more than 98% speci-
ficity. These RTs were single-use, disposable-chamber, 
in vitro, qualitative, immunochromatographic assays that 
could detect anti-HBs and anti-HBe. The RTs allowed the 
detection of antibodies in serum, plasma and whole blood 
and used 100 µL of sample per assay. Each assay was 
completed in 10-15 min. Assays were conducted accord-
ing to the manufacturer s´ recommendations.
The sensitivity of the anti-HBs RT was also evaluated 
in the following two additional subgroups: (1) vaccinated 
individuals (isolated anti-HBs reactive) and previously 
HBV infected (anti-HBs/anti-HBc reactive) and (2) indi-
viduals with anti-HBs titers lower than 100 IU/mL and 
titers higher than 100 IU/mL. These cutoff values were 
chosen because approximately 85% of individuals who 
presented anti-HBs titers above 100 IU/mL after primary 
vaccination still had anti-HBs 22 years after vaccination.
The sensitivity of the anti-HBe RT was evaluated us-
ing the presence of an active HBV infection (anti-HBe 
reactive/HBsAg reactive), compared to a previous HBV 
infection (anti-HBe reactive/HBsAg non-reactive).
The detection of anti-HBs and anti-HBe in the serum 
samples by EIA or ECLIA was defined in the present 
study as the gold standard for the assessment of the sen-
sitivity, speciﬁcity, positive predictive value (PPV), and 
negative predictive value (NPV) of each RT. To evaluate 
the deviation between the observed and expected val-
ues in each group, the X2 test or Fisher’s exact test were 
used. The Kappa coefficient (k) was used to assess the 
degree of agreement between the reference panel and the 
RT under analysis. Two-tailed p-values < 0.05 were con-
sidered statistically significant.
In this study, 2,330 individuals donated serum 
samples for the anti-HBs RT evaluation. The mean 
age ± standard deviation was 48 (± 13.99) years, 29 
(± 20.39) years and 33 (± 14.41) years for GI, GII and 
GIII, respectively. Anti-HBs EIA for GI, GII and GIII 
showed 133, 572 and 107 reactive results, respectively, 
and 290, 954 and 274 non-reactive results, respectively. 
The sensitivity of the anti-HBs RT was relatively low 
in all groups, but a higher sensitivity was found in GII: 
51.05% (292/572) compared to GI: 50.38% (67/133) and 
GIII: 46.73% (50/107). The specificity values were above 
98.00% for all groups, and the concordance ranged from 
53.32% to 57.66% in all groups (Table I).
Samples that presented a false-negative result for 
anti-HBs in RT had low mean optical density/cut-off 
value ratio (OD/CO) values by ELISA compared to those 
samples considered anti-HBs true positive samples (Ta-
ble II). Better sensitivity results of anti-HBs RT were 
observed in samples previously infected with HBV com-
pared to vaccinated individuals in all groups and samples 
with anti-HBs titers higher than 100 IU/mL compared to 
titers lower than 100 IU/mL in all groups (Table III).
A total of 1,195 individuals were included in the anti-
HBe RT evaluation. The mean age ± standard deviation 
was 45.3 (± 14.6) years, 31.6 (± 20.7) years, 30.4 (± 12.7) 
years for GI, GII and GIII, respectively. Anti-HBe results 
by ECLIA for GI, GII and GIII showed 113, 87 and 17 
reactive results and 53, 701 and 224 non-reactive results, 
respectively. The sensitivities were 76.99% (87/111) in 
GI, 11.76% (2/17) in GIII and 10.34% (9/87) in GII. Spec-
ificity values were above 95.00% for all groups, and a 
high concordance between anti-HBe RT and EIA was 
observed in GI (k = 65.36%) (Table I).
False negative anti-HBe samples by anti-HBeAg RT 
presented higher mean OD/CO values by ECLIA com-
pared to the true positive anti-HBe samples (Table II). The 
anti-HBe RT also had a higher sensitivity in those individu-
als who presented active HBV infection compared to those 
who were previously infected (Table III).
RTs are useful tools for HBV screening in low resource 
areas and/or emergency settings, but limited studies have 
been conducted to evaluate the performance of RTs for 
anti-HBe (El-Ghitany & Farghaly 2013) and anti-HBs (Oh 
et al. 1999, Whang & Um 2005, Cha et al. 2006, Bottero 
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TABLE III
Sensitivity of the anti-HBs rapid test (Imuno-Rápido anti-HBsAg™) 
according to the anti-HBs titer and HBV status and sensitivity of anti-HBe rapid test (Imuno-Rápido anti-HBeAg™)
Evaluated groups
Anti-HBs Anti-HBe
Sensitivity of anti-HBs rapid test  
according to HBV status
Sensitivity of anti-HBs rapid test  
according to anti-HBs titer
Sensitivity of anti-HBe rapid test 







anti-HBs titers  
< 100 IU/mL
n (%)
anti-HBs titers  
≥ 100 IU/mL
n (%)








28/47 (59.57) 39/86 (45.35) 7/51 (13.72) 60/82 (73.17) 84/100 (84.00) 3/13 (23.10)
Group II
Low prevalence
134/176 (76.14) 158/396 (39.90) 40/268 (14.92) 252/304 (82.89) 1/1 (100.00) 8/86 (9.30)
Group III
High vulnerability
15/18 (83.33) 35/89 (39.32) 2/41 (4.87) 48/66 (72.72) 1/3 (33.30) 1/14 (7.10)
All groups 177/241(73.44) 232/571 (40.63) 49/360(13.61) 360/452 (79.65) 86/104 (80.77) 12/113 (10.62)
a: anti-HBs/anti-HBc reactive; b: anti-HBs alone; c: anti-HBe reactive /HBsAg reactive; d: anti-HBe reactive/HBsAg non-reac-
tive; IU: international units; n: number of samples.
TABLE II
Mean values of OD/CO from EIE among false-negatives and true positive rapid tests for anti-HBs and anti-HBe detection
Group
Imuno-Rápido anti-HBsAg™ Imuno-Rápido anti-HBeAg™
Anti-HBs FN
OD/CO mean ± SD
Anti-HBs TP
OD/CO mean ± SD p-value
Anti-HBe FN
OD/CO mean ± SD
Anti-HBe TP
OD/CO mean ± SD p-value
Group I
Reference centres
5.91 ± 5.44 29.56 ± 22.84 p < 0.0001 0.264 ± 0.316 0.025 ± 0.122 p < 0.0001
Group II
Low prevalence
5.00 ± 6.46 35.21 ± 24.87 p < 0.0001 0.370 ± 0.357 0.099 ± 0.282 p = 0.0006
Group III
High vulnerability
10.76 ± 8.98 30.60 ± 27.23 p < 0.0001 0.349 ± 0.422 0.005 ± 0.001 p = 0.1791
All groups 6.03 ± 7.02 33.67 ± 24.90 p < 0.0001 0.347 ± 0.357 0.032 ± 0.142 p < 0.001
FN: false negative; OD/CO: optical density/cutoff; SD: standard deviation; TP: true positive.
et al. 2013, 2016, El-Ghitany & Farghaly 2013, Wu et al. 
2016). In the present study, two RTs (Imuno-Rápido anti-
HBeAg™ and Imuno-Rápido anti-HBsAg™) were evaluated 
and showed high specificity and low sensitivities regardless 
of the endemicity profile of the populations analysed.
Anti-HBs RT showed high specificity values regard-
less of the endemicity profile of the populations evalu-
ated and had similar values as those observed in France 
(97.80%), Taiwan (96.5%) and Egypt (95.08%) (Bottero 
et al. 2013, El-Ghitany & Farghaly 2013, Wu et al. 2016). 
These assays demonstrate an ability to identify true nega-
tive samples. Additionally, the sensitivity of anti-HBs RT 
was low in all groups (less than 51.5%), which is similar 
to what was observed using whole blood with Quick Pro-
file (Lumiquick, USA) (58.08%) and sera samples with 
Advanced Test Quality One Step (Intec Products, China) 
(64.20%) (Bottero et al. 2013, El-Ghitany & Farghaly 
2013). Furthermore, some studies have shown that the test 
sensitivity is above 91% in volunteers and children (Bot-
tero et al. 2016, Wu et al. 2016), and a meta-analysis study 
showed a pooled sensitivity and specificity of 93.2% and 
93.1%, respectively. However, RTs from different manu-
facturers were evaluated in those studies (General Biolog-
icals Corporation, Genedia, Daewoong, Asan, Lumiquick 
diagnostics, and SD) (Shivkumar et al. 2012).
An interesting finding was the high sensitivity of the 
anti-HBs RT when samples with high values of OD/CO 
in EIE or high antibody titers (above 100 IU/mL) were 
used. The sensitivity of these anti-HBs RTs was the same 
as previously described (El-Ghitany & Farghaly 2013, 
Wu et al. 2016), showing that these tests may be useful 
for screening individuals with a high reactivity for anti-
HBs. The RT for anti-HBs detection also demonstrated 
better performance in individuals with previous infec-
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tions compared to individuals with a vaccine response. 
This difference may be due to the low anti-HBs titers 
obtained by vaccination in different circumstances, in-
cluding immunosuppression, liver disease, renal failure, 
smoking, obesity, improper vaccine administration, short 
time interval between the second and third dose, age of 
the subject when vaccinated and the progressive decline 
of antibody titers in a large proportion of most individu-
als 9-11 years after vaccination (Kwon & Lee 2011).
In agreement with previous studies, anti-HBs RT and 
anti-HBe RT also demonstrated high specificity (above 
96.00%) in all groups analysed, demonstrating an ability 
to discriminate negative results. The best performance of 
the anti-HBe RT was observed among patients referred 
to the Viral Hepatitis Clinic (65.36%) demonstrating the 
usefulness of this assay in the evaluation of seroconver-
sion of HBeAg to anti-HBe in patients who have HBV. 
This is a favorable outcome that might be associated 
with a better prognosis among HBV patients according 
to the guidelines issued by the BMH (2011).
The anti-HBe RT was highly effective when samples 
with HBV active infection or samples with low values 
of OD/CO by ECLIA were considered. Conversely, El-
Ghitany and Farghaly (2013) did not observe this find-
ing which was probably due to differences in the RT and 
gold standard tests used.
In conclusion, RTs for anti-HBs and anti-HBe evalu-
ated in the present study showed low sensitivity and high 
specificity indicating their use as a screening method in 
high HBV endemicity areas.
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